Remodelage microvasculaire et ischémie coronaire dans l'hypertension artérielle

Translated title of the contribution: Coronary microvascular remodeling and ischaemia in hypertension

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

An increasing amount of evidence suggests that the development of myocardial ischemia in hypertensive patients without angiographically demonstrable coronary artery disease, may at least in part be due to anatomic and functional abnormalities of the coronary microvasculature. Studies employing cardiac imaging techniques, in particular positron emission tomography (PET), have demonstrated that the coronary flow reserve (CFR), i.e. the ratio of myocardial blood flow (MBF) during near maximal vasodilatation (pharmacologically-induced) to resting MBF, is significantly impaired in hypertensive patients with or without left ventricular hypertrophy (LVH). In the absence of significant coronary stenoses, an abnormal CFR is suggestive of dysfunction of the coronary microcirculation. In parallel, mechanistic studies have suggested that microvascular dysfunction can be a result of several interacting mechanisms, including myocyte remodeling, vascular (intramyocardial coronary arteriole) remodeling, and decreased vasodilatory capacity of the coronary microcirculatory endothelium. Furthermore, PET studies of patients with hypertrophic cardiomyopathy have demonstrated that the severity of CFR impairment is an independent predictor of clinical deterioration and death in these patients and may precede clinical deterioration by years. Similarly, preliminary studies in hypertensive patients with or without LVH have suggested that long-term therapy with the combination of the ACE inhibitor, perindopril 2 mg, and the diuretic, indapamide 0.625 mg, may improve the status of coronary microcirculation in these patients, although these findings need to be substantiated in larger studies.

Original languageFrench
Pages (from-to)25-30
Number of pages6
JournalAmerican Journal of Cardiovascular Drugs
Volume4
Issue numberSPEC. ISS. 1
DOIs
Publication statusPublished - 2004

Fingerprint

Ischemia
Hypertension
Left Ventricular Hypertrophy
Microcirculation
Positron-Emission Tomography
Cardiac Imaging Techniques
Indapamide
Perindopril
Coronary Stenosis
Hypertrophic Cardiomyopathy
Arterioles
Microvessels
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Vasodilation
Muscle Cells
Endothelium
Myocardial Ischemia
Coronary Artery Disease
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Remodelage microvasculaire et ischémie coronaire dans l'hypertension artérielle. / Camici, Paolo G.

In: American Journal of Cardiovascular Drugs, Vol. 4, No. SPEC. ISS. 1, 2004, p. 25-30.

Research output: Contribution to journalArticle

@article{de196a938f9b47599c79e37e09033694,
title = "Remodelage microvasculaire et isch{\'e}mie coronaire dans l'hypertension art{\'e}rielle",
abstract = "An increasing amount of evidence suggests that the development of myocardial ischemia in hypertensive patients without angiographically demonstrable coronary artery disease, may at least in part be due to anatomic and functional abnormalities of the coronary microvasculature. Studies employing cardiac imaging techniques, in particular positron emission tomography (PET), have demonstrated that the coronary flow reserve (CFR), i.e. the ratio of myocardial blood flow (MBF) during near maximal vasodilatation (pharmacologically-induced) to resting MBF, is significantly impaired in hypertensive patients with or without left ventricular hypertrophy (LVH). In the absence of significant coronary stenoses, an abnormal CFR is suggestive of dysfunction of the coronary microcirculation. In parallel, mechanistic studies have suggested that microvascular dysfunction can be a result of several interacting mechanisms, including myocyte remodeling, vascular (intramyocardial coronary arteriole) remodeling, and decreased vasodilatory capacity of the coronary microcirculatory endothelium. Furthermore, PET studies of patients with hypertrophic cardiomyopathy have demonstrated that the severity of CFR impairment is an independent predictor of clinical deterioration and death in these patients and may precede clinical deterioration by years. Similarly, preliminary studies in hypertensive patients with or without LVH have suggested that long-term therapy with the combination of the ACE inhibitor, perindopril 2 mg, and the diuretic, indapamide 0.625 mg, may improve the status of coronary microcirculation in these patients, although these findings need to be substantiated in larger studies.",
author = "Camici, {Paolo G.}",
year = "2004",
doi = "10.2165/00129784-200404991-00008",
language = "Francese",
volume = "4",
pages = "25--30",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "SPEC. ISS. 1",

}

TY - JOUR

T1 - Remodelage microvasculaire et ischémie coronaire dans l'hypertension artérielle

AU - Camici, Paolo G.

PY - 2004

Y1 - 2004

N2 - An increasing amount of evidence suggests that the development of myocardial ischemia in hypertensive patients without angiographically demonstrable coronary artery disease, may at least in part be due to anatomic and functional abnormalities of the coronary microvasculature. Studies employing cardiac imaging techniques, in particular positron emission tomography (PET), have demonstrated that the coronary flow reserve (CFR), i.e. the ratio of myocardial blood flow (MBF) during near maximal vasodilatation (pharmacologically-induced) to resting MBF, is significantly impaired in hypertensive patients with or without left ventricular hypertrophy (LVH). In the absence of significant coronary stenoses, an abnormal CFR is suggestive of dysfunction of the coronary microcirculation. In parallel, mechanistic studies have suggested that microvascular dysfunction can be a result of several interacting mechanisms, including myocyte remodeling, vascular (intramyocardial coronary arteriole) remodeling, and decreased vasodilatory capacity of the coronary microcirculatory endothelium. Furthermore, PET studies of patients with hypertrophic cardiomyopathy have demonstrated that the severity of CFR impairment is an independent predictor of clinical deterioration and death in these patients and may precede clinical deterioration by years. Similarly, preliminary studies in hypertensive patients with or without LVH have suggested that long-term therapy with the combination of the ACE inhibitor, perindopril 2 mg, and the diuretic, indapamide 0.625 mg, may improve the status of coronary microcirculation in these patients, although these findings need to be substantiated in larger studies.

AB - An increasing amount of evidence suggests that the development of myocardial ischemia in hypertensive patients without angiographically demonstrable coronary artery disease, may at least in part be due to anatomic and functional abnormalities of the coronary microvasculature. Studies employing cardiac imaging techniques, in particular positron emission tomography (PET), have demonstrated that the coronary flow reserve (CFR), i.e. the ratio of myocardial blood flow (MBF) during near maximal vasodilatation (pharmacologically-induced) to resting MBF, is significantly impaired in hypertensive patients with or without left ventricular hypertrophy (LVH). In the absence of significant coronary stenoses, an abnormal CFR is suggestive of dysfunction of the coronary microcirculation. In parallel, mechanistic studies have suggested that microvascular dysfunction can be a result of several interacting mechanisms, including myocyte remodeling, vascular (intramyocardial coronary arteriole) remodeling, and decreased vasodilatory capacity of the coronary microcirculatory endothelium. Furthermore, PET studies of patients with hypertrophic cardiomyopathy have demonstrated that the severity of CFR impairment is an independent predictor of clinical deterioration and death in these patients and may precede clinical deterioration by years. Similarly, preliminary studies in hypertensive patients with or without LVH have suggested that long-term therapy with the combination of the ACE inhibitor, perindopril 2 mg, and the diuretic, indapamide 0.625 mg, may improve the status of coronary microcirculation in these patients, although these findings need to be substantiated in larger studies.

UR - http://www.scopus.com/inward/record.url?scp=4544295792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544295792&partnerID=8YFLogxK

U2 - 10.2165/00129784-200404991-00008

DO - 10.2165/00129784-200404991-00008

M3 - Articolo

VL - 4

SP - 25

EP - 30

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - SPEC. ISS. 1

ER -